Linked inTwitter

The 52:52:52 project, launching both on this site and on social media in early 2024 will help you address 52 issues with 52 responses over 52 weeks.

A Mundane Comedy is Dominic Kelleher's new book, which will be published in mid 2024. The introduction is available here and further extracts will appear on this site and on social media in the coming months.

This site addresses what's changing, in our own lives, in our organisations, and in wider society. You'll learn about key changes across more than 150 areas, ranging from ageing and time, through nature and animals, to kindness and love...and very much else inbetween.

Halcyon's aim is to help you reflect on how you can better deal with related change in your own life.

China

What's Changing? - Travel
Travel
Halcyon Identifies 17 January 2024

 

Please see below selected recent travel-related change.

 

See also:

 

January 2024

What's Changing? - Privacy

Privacy

 

Please see below selected recent privacy-related change.

 

See also:

 

December 2023

  • AI has become a major tool for computer-generated non-consensual pornography - a problem that disproportionately affects women. In September 2023 alone, 24 million people visited websites that gave them the ability to “undress” - or “nudify” - people in photographs using machine-learning technology.

 

October 2023

What's Changing? - Belt & Road Initiative
Belt & Road Initiative
Halcyon In Business 7 December 2023

 

Introduction

China's Belt and Road infrastructure initiative is one of the most ambitious geopolitical projects ever. By 2027, it aims to dish out an estimated $1.3 trillion in loans, around ten times what the US spent on the Marshall Plan in the aftermath of World War II. As China increases its investment in the West, will countries' loyalty shift toward Beijing? About 80 countries have already joined, and dozens more are flirting with the idea. For a world that badly needs more and better infrastructure, Belt and Road is a good thing

On CRISPR

Genetics

 

40%: The percentage of patients reported to have responded to one of the most advanced CRISPR cancer therapy studies to be tested in China. China is far ahead of the US in CRISPR cancer studies due to its less stringent approval requirements, but the US and Europe are set to see their first human trials of the gene-editing technique this year. With potentially transformative implications across medicine, agriculture, and even chemical products, CB Insights' 5,200-word CRISPR deep dive unpacks the science behind the technology, its applications, controversies it’s stirred up, and where CRISPR may take us next.